What is NOT a primary indication for the use of DPP-4 inhibitors?

DPP-4 inhibitors are primarily used for the management of Type 2 diabetes. Their main mechanisms of action involve increasing incretin levels, which in turn help to lower blood glucose levels by enhancing insulin release and reducing glucagon levels. They also have a role in protecting the kidneys from the complications associated with diabetes, thus providing a reduction of renal risk.

Weight loss, while an important aspect of diabetes management, is not a primary indication for the use of DPP-4 inhibitors; these medications are generally weight-neutral. Therefore, weight loss does not directly correlate with the use of DPP-4 inhibitors when treating Type 2 diabetes, which is why it is identified as the option that is NOT a primary indication for their use.

The other options—management of Type 2 diabetes, reduction of renal risk, and decreased glucagon release—are all integral aspects of how DPP-4 inhibitors function and why they are prescribed.